SVNS

Solvonis Therapeutics PLC

Health Care First-pass screen £16m

260/1000 Overall fit

AI beneficiary 35% 30

Operating leverage 25% 20

Valuation 25% 22

Downside protection 15% 32

First-pass take

Pre-revenue clinical-stage biotech with Phase 3 lead asset (SVN-001) in alcohol use disorder. AI discovery platform mentioned but internal-focused. Net cash £1.7m provides ~6-month runway; going concern uncertainty disclosed. Extreme share dilution (3x in 2025). Healthcare exposure defensible but execution risk dominates.

Flags

loss-makingpre-revenuegoing-concernclinical-stagemicro-caprecent-m-and-aextreme-dilutionexecution-riskno-valuation-data